Xenon Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Xenon Pharmaceuticals has a total shareholder equity of $797.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $835.9M and $38.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$654.02m |
| Equity | US$797.81m |
| Total liabilities | US$38.09m |
| Total assets | US$835.90m |
Recent financial health updates
Companies Like Xenon Pharmaceuticals (NASDAQ:XENE) Are In A Position To Invest In Growth
Jan 21
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 20Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Jul 05Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22Recent updates
Companies Like Xenon Pharmaceuticals (NASDAQ:XENE) Are In A Position To Invest In Growth
Jan 21Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Jan 16Estimating The Intrinsic Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Nov 25We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 20Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Aug 09Is There An Opportunity With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) 37% Undervaluation?
Aug 09Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Jul 05We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Apr 16Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
Jun 13Sizing Up Xenon Pharmaceuticals
Dec 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Aug 05Financial Position Analysis
Short Term Liabilities: XENE's short term assets ($659.6M) exceed its short term liabilities ($29.7M).
Long Term Liabilities: XENE's short term assets ($659.6M) exceed its long term liabilities ($8.4M).
Debt to Equity History and Analysis
Debt Level: XENE is debt free.
Reducing Debt: XENE has no debt compared to 5 years ago when its debt to equity ratio was 20.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XENE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: XENE has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 34.2% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 01:58 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xenon Pharmaceuticals Inc. is covered by 24 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| John Newman | Canaccord Genuity |